Creating a Global Company

Our Specialty Portfolio • Indication - For LABCC (locally advanced basal cell carcinoma) Odomzo • Currently marketed in US, Germany, France, Denmark, Switzerland, Australia and Israel Yonsa • Indication - For metastatic castration resistant prostate cancer in combination with methylprednisolone . Bromsite Xelpros Sprinkle Portfolio • Launched in US in May 2018 SUN PHARMA • Indication - For prevention of ocular pain & treatment of inflammation following cataract surgery Launched in US in November 2016 • Indication - For reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension • BAK (Benzalkonium chloride) free form of latanoprost • Launched In US in January 2019 Products using sprinkle technology for patients who have difficulty swallowing • Sprinkle versions of metoprolol (cardiology), rosuvastatin (cardiology) & duloxetine (neuro- psychiatry) commercialized in US between 2018-2019 Therapeutic solutions for long-term care (LTC) patients 9

View entire presentation